hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06319365 id: gurcansolmaz briefTitle: Yoga on Women's Blood Pressure, Sexual Life, And Marital Compliance overallStatus: RECRUITING date: 2023-03-01 date: 2024-03-22 date: 2024-03-22 date: 2024-03-20 date: 2024-03-25 name: University of Yalova class: OTHER briefSummary: Introduction This study will examine the effects of a 12-week yoga program consisting of one-hour sessions three times a week on blood pressure, sexual life and marital adjustment among hypertensive women. Hypertension can adversely affect vascular health and affect marital relationships by contributing to sexual dysfunction.
Method. The study will be a pre-post test randomized controlled study in accordance with CONSORT rules. Personal Information Form, Bloood pressure measurement, Arizona Sexual Experience Scale and Marital Adjustment Test will be used for data collection. conditions: Hypertension conditions: Sexuality studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 70 type: ESTIMATED name: yoga measure: blood presure sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yalova University status: RECRUITING city: Yalova country: Turkey name: GÜRCAN SOLMAZ role: CONTACT email: gurcansolmaz@hotmail.com lat: 40.65501 lon: 29.27693 hasResults: False
nctId: NCT06319352 id: HUM00243293 briefTitle: Evaluation of Quality-of-Life Improvements Using UroShield Device overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2024-10 date: 2024-10 date: 2024-03-20 date: 2024-04-26 name: University of Michigan class: OTHER name: Nanovibronix briefSummary: The goal of this pilot study is to test key elements of the full study that will follow, including recruitment and retention strategies, intervention delivery, laboratory testing, data collection methods, and adherence to study protocol.
Results of this pilot study will inform the investigators as to necessary protocol modifications and overall feasibility for the larger randomized clinical trial to follow. conditions: Quality of Life conditions: Catheter-Associated Urinary Tract Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DEVICE_FEASIBILITY masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 16 type: ESTIMATED name: Active UroShield name: Sham UroShield measure: Recruitment rate measure: Device use adherence measure: Device accountability measure: Efficiency of data collection sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319326 id: Postfeed Intestinal Perfusion briefTitle: Intestinal Perfusion After Feeding in Preterm and Term Infants overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2024-06-30 date: 2024-08-31 date: 2024-03-20 date: 2024-03-20 name: The Hospital for Sick Children class: OTHER name: Xiamen Children's Hospital briefSummary: This is a pilot exploratory observational prospective cohort phase I study. In this study, we will gather preliminary data to evaluate (i) the magnitude of changes in blood flow in the bowel before and after feeding and (ii) the differences between preterm and term infants. conditions: Premature conditions: Necrotizing Enterocolitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. measure: Time-averaged mean velocity of the superior mesenteric artery measure: Bowel wall perfusion sex: ALL maximumAge: 4 Weeks stdAges: CHILD facility: Children's Hospital of Fudan University (Xiamen Branch) city: Xiamen state: Fujian zip: 361000 country: China name: Haitao Zhu, MD role: CONTACT phone: +86-592-2529586 email: haitao_zhu@fudan.edu.cn name: Haitao Zhu, MD role: PRINCIPAL_INVESTIGATOR lat: 24.47979 lon: 118.08187 hasResults: False
nctId: NCT06319313 id: JMT101-013 briefTitle: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-07-01 date: 2027-12-01 date: 2024-03-20 date: 2024-03-20 name: Shanghai JMT-Bio Inc. class: INDUSTRY briefSummary: This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）. conditions: Squamous Cell Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 534 type: ESTIMATED name: JMT101 name: docetaxel name: HB1801 measure: Overall response rate (ORR) measure: Overall Survival (OS) measure: Incidence and severity of adverse events (AE) and serious adverse events (SAE) measure: Progression-free Survival (PFS) measure: Disease Control Rate (DCR) measure: Duration of response（DOR） measure: JMT101 Concentrations in Plasma measure: Total and Free Docetaxel Concentrations in Plasma sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319300 id: 20240115023245436 briefTitle: Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards overallStatus: RECRUITING date: 2024-04-19 date: 2026-03-20 date: 2026-05-20 date: 2024-03-20 date: 2024-04-22 name: Shanghai Zhongshan Hospital class: OTHER name: Shanghai Fifth People's Hospital,Fudan University briefSummary: Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to include 140 patients admitted to the general ward for subcutaneous insulin therapy, who were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence assisted insulin dosimetry system to adjust the insulin dose to control their blood glucose, and the other group with a physician instituted insulin dosimetry adjustments to control their blood glucose. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups. conditions: Diabetes Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 140 type: ESTIMATED name: AI-assisted insulin dose adjustment model name: doctor's insulin dose adjustment measure: time in target range (3.9-10.0 mmol/L ) measure: sensor glucose measure: capillary blood sugar measure: hypoglycaemic event measure: hyperglycaemic event measure: insulin dosage measure: satisfaction score of doctors measure: Length of hospitalisation measure: Other/Serious Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan Hospital, Fudan University status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Xiaoying Li role: CONTACT phone: +862164041990 email: li.xiaoying@zs-hospital.sh.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06319287 id: PRO-00125 briefTitle: Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU) overallStatus: RECRUITING date: 2024-02-27 date: 2025-04-05 date: 2025-07-12 date: 2024-03-20 date: 2024-04-16 name: Rion Inc. class: INDUSTRY name: Professional Education and Research Institute briefSummary: A Phase 2a Multi-Center, Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Topically Applied PEP-TISSEEL in Subjects with Diabetic Foot Ulcers (DFU) conditions: Diabetic Foot Ulcer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multi-center, Open Label, Randomized Controlled Clinical Trial Evaluating the Effect of PEP/TISSEEL in the Treatment of Diabetic Foot Ulcers primaryPurpose: TREATMENT masking: NONE maskingDescription: Open Label count: 40 type: ESTIMATED name: PEP (Purified Exosome Product) / TISSEEL measure: Wound Closure measure: Safety measure: Percent Area Reduction of Wound at 12 Weeks measure: Visual Analogue Scale (VAS) for Pain over 12 weeks measure: Semmes-Weinstein Score measure: Wound-Q Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Professional Education & Research Institute (PERI) status: RECRUITING city: Blue Ash state: Ohio zip: 45242 country: United States name: Charles Zelen, M.D. role: CONTACT phone: 540-344-3668 email: cmzelen@mriedu.com name: Morgan Zelen role: CONTACT phone: 203-671-5915 email: mzelen@periedu.com lat: 39.232 lon: -84.37827 hasResults: False
nctId: NCT06319274 id: COMBAT-ARF briefTitle: Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure acronym: COMBAT-ARF overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-30 date: 2026-12-30 date: 2024-03-20 date: 2024-03-20 name: Pär Johansson class: OTHER briefSummary: The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival. conditions: Acute Respiratory Failure conditions: Endothelial Dysfunction conditions: Pulmonary Infection studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization active/placebo (1:1) parallel arms primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The preparation will be done by an unblinded study nurse independent of the including ICU´s, who will be responsible for preparing the investigational drug to be administered in a blinded fashion. Iloprost is a colorless fluid that is to be diluted in 0.9% saline. The infusion pump containing diluted active drug and placebo will be identical in both looks and behavior. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 450 type: ESTIMATED name: Iloprost name: Isotonic saline measure: 28-day mortality measure: 90-day mortality measure: Vasopressor-free days measure: Renal replacement-free days measure: Mechanical ventilation free days measure: Serious adverse reactions (SARs) measure: Serious adverse events (SAEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital city: Copenhagen zip: 2400 country: Denmark name: Niels E Clausen, MD role: CONTACT name: Niels E Clausen, MD role: PRINCIPAL_INVESTIGATOR lat: 55.67594 lon: 12.56553 facility: Dept. of Intensive Care, Copenhagen University Hospital Herlev city: Herlev zip: 2730 country: Denmark name: Peter Soee-Jensen, MD role: CONTACT name: Peter Soee-Jensen, MD role: PRINCIPAL_INVESTIGATOR lat: 55.72366 lon: 12.43998 facility: Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital city: Hillerød zip: 3400 country: Denmark name: Morten Bestle, MD role: CONTACT name: Morten Bestle, MD role: PRINCIPAL_INVESTIGATOR lat: 55.92791 lon: 12.30081 facility: Department of Anesthesia and Intensive Care Medicine, Zealand University Hospital city: Køge zip: 4600 country: Denmark name: Lars Peter K Andersen, MD, PhD role: CONTACT name: Lars Peter K Andersen, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 55.45802 lon: 12.18214 hasResults: False
nctId: NCT06319261 id: 858623 briefTitle: Efficacy of Guided Biofilm Therapy (GBT) for Treatment of Deep Periodontal Pockets. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: University of Baghdad class: OTHER briefSummary: the aim of the study is to evaluate the efficacy of guided biofilm therapy (GBT) for treatment of deep periodontal pockets.
1- To compare the change in the clinical periodontal parameters and microbiological parameters by using real time PCR for P. gingivalis, Aggregatibacter actinomycetemcomitans and Filifactor alocis among sites treated by GBT and conventional hand instrumentation after a period of 3 months and to assess the level of the selected periodontal pathogens in deep periodontal pockets and to estimate and compare deep periodontal pockets which need surgery after 3 months of non-surgical treatment by GBT and conventional hand instrumentation.
2. Sites treated with conventional manual instrumentation only. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 25 type: ESTIMATED name: guided biofilm therapy name: root surface debridement measure: Periodontal pocket depth (PPD) measure: Plaque index measure: Bleeding on probing measure: Relative attachment level measure: Changes in the bacterial load sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06319248 id: 24-000121 briefTitle: Use of Midodrine in Septic Shock Patients overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-05-30 date: 2029-07-30 date: 2024-03-20 date: 2024-04-16 name: Mayo Clinic class: OTHER briefSummary: This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall. conditions: Sepsis conditions: Low Blood Pressure studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 270 type: ESTIMATED name: Midodrine name: Placebo measure: Time alive and without vasopressor support measure: Total vasopressor requirements measure: Central venous access duration measure: Cumulative fluid balance over the first 48 hours measure: Cumulative fluid balance up to 7 days of ICU stay measure: ICU Length of Stay measure: Hospital Length of Stay measure: ICU, hospital, and organ support-free days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Minnesota city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06319235 id: DUO2022_01 id: 2022-002412-23 type: EUDRACT_NUMBER briefTitle: Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® overallStatus: RECRUITING date: 2023-10-27 date: 2025-12-31 date: 2025-12-31 date: 2024-03-19 date: 2024-03-19 name: MB PHARMA s.r.o. class: INDUSTRY briefSummary: DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa.
The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing. conditions: Surgical Site Infection conditions: Staphylococcus Aureus Infection conditions: Pseudomonas Aeruginosa Infection conditions: Bacterial Infections conditions: Surgical Wound Infection studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 52 type: ESTIMATED name: IMP name: Placebo measure: Primary endpoint - Cohort 1 measure: Primary endpoint - pooled Cohorts 1 & 2 measure: Safety endpoints (assessed in pooled Cohorts 1 & 2) measure: Microbiological endpoints (assessed in pooled Cohort 1 and Cohort 2) measure: Clinical efficacy endpoints sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Anne's University Hospital Brno status: RECRUITING city: Brno state: Czech Republic zip: 602 00 country: Czechia name: Dominik Maduda, MUDr. role: CONTACT phone: +420 543 182 432 email: dominik.maduda@fnusa.cz name: Kateřina Bílá, MUDr. role: CONTACT phone: +420 543 182 451 email: katerina.bila@fnusa.cz lat: 49.19522 lon: 16.60796 hasResults: False
nctId: NCT06319222 id: 23-007870 briefTitle: Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC) acronym: DALC overallStatus: RECRUITING date: 2024-03-12 date: 2024-09 date: 2025-04 date: 2024-03-19 date: 2024-04-01 name: Mayo Clinic class: OTHER name: Ria Health briefSummary: The purpose of this study is to determine whether a multidisciplinary digital clinic will improve health outcomes, reduce costs, increase access, and improve provider satisfaction.
The primary aim of this study is to improve clinical outcomes in patients with ALD through the implementation of a novel digital health platform for personalized multi-disciplinary treatment of patients with ALD and AUD. Secondary aims include improvement in provider and patient-reported outcomes including satisfaction with AUD treatment. conditions: Alcohol Use Disorder conditions: Liver Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: DALC Digital Clinic measure: Median delta MELD-3.0 from baseline to end of study. measure: Sustained alcohol abstinence measure: Reduction of Number of hospitalizations measure: Greater provider satisfaction in DALC arm sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Arizona status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Blanca C Lizaola-Mayo, MD role: CONTACT phone: 480-342-1094 email: dalc@mayo.edu lat: 33.50921 lon: -111.89903 facility: Mayo Clinic status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Douglas Simonetto, MD role: CONTACT phone: 507-284-1649 email: dalc@mayo.edu name: Camille Kezer, MD role: CONTACT phone: 507-284-2687 email: dalc@mayo.edu lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06319209 id: 2024KY023 briefTitle: Timing of Surgery and the Evolution of Postoperative Outcomes in Breast Cancer Patients Undergoing Surgical Intervention Following Recovery From SARS-CoV-2 Infection overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-01 date: 2023-03-31 date: 2024-03-31 date: 2024-03-19 date: 2024-03-19 name: Fujian Medical University Union Hospital class: OTHER briefSummary: Perioperative SARS-CoV-2 infection significantly increases the risk of postoperative complications and mortality, while also exerting long-lasting impacts on multiple organs and systems. Due to the curtailment or cessation of non-emergency surgeries during the initial phase of the pandemic, there is a lack of evidence regarding the optimal timing and medium- to long-term postoperative outcomes of surgical intervention in breast cancer patients with prior SARS-CoV-2 infection, particularly after vaccination. We aim to investigate whether prior SARS-CoV-2 infection increases the risk of postoperative adverse outcomes in breast cancer patients and determine the optimal timing for surgical intervention during the pandemic, as well as to longitudinally assess the evolution of postoperative adverse outcomes within one year after COVID-19 and identify associated risk factors. conditions: Breast Cancer conditions: COVID-19 conditions: Postoperative Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 392 type: ACTUAL name: Preoperative resolved COVID-19 measure: 30-day postoperative outcomes measure: Postoperative outcomes at the time of the initial tumor assessment after surgery measure: 12-month postoperative outcomes sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Medical University Union Hospital city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06319196 id: Clear Me briefTitle: Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma acronym: ClearMe overallStatus: RECRUITING date: 2024-05-01 date: 2027-02-15 date: 2030-02-15 date: 2024-03-19 date: 2024-04-22 name: University Health Network, Toronto class: OTHER briefSummary: Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) following definitive surgery for high risk melanoma. Patients will be allocated to either Arm A or Arm B via the process of randomization. The randomization process will be stratified according to stage (Stage 2A/2B/3A/3B/3C/3D or 4), to ensure absolute balance between stage groups. The investigators are choosing only 1 stratification factor, disease stage, as the investigators consider stage being the most significant prognosticating variable. Each stage represents a biologically distinct entity with varying recurrence rate outcomes. Block randomization will be performed to ensure equal sample sizes in the combination and monotherapy arms. At least 54 patients will be included in the randomized part of the study. The investigators are expecting approximately 20% of the patients to have detectable ctDNA after definite surgery. Therefore, approximately 270 patients are expected to be enrolled and tested for ctDNA in the entire study. conditions: Cutaneous Melanoma conditions: Melanoma Stage IV conditions: Mucosal Melanoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Opdualag name: Nivolumab measure: Clearance of ctDNA at 12 months after starting adjuvant treatment. ctDNA clearance is defined as no detection of plasma ctDNA measure: Recurrence-free survival (RFS) measure: Number and severity of treatment related adverse events according to CTCAE v5.0. measure: Clearance of ctDNA measure: Measured changes of biomarker ctDNA measure: Methylation patterns of biomarker ctDNA using circulating free methylated DNA immunoprecipitation and sequencing (cfMeDIPseq) assay and correlation with ctDNA total variant allele frequency (VAF) detection. measure: Quality of life assessment using Quality of Life Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UHN- Princess Margaret Cancer Center status: RECRUITING city: Toronto state: Ontario zip: M5G 1Z5 country: Canada name: Anna Spreafico, MD role: CONTACT phone: 416-946-2263 email: anna.spreafico@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06319183 id: 2023tjdxsy045 briefTitle: The Regulatory Function of Inhaled Asthma Medication Salbutamol on Thermogenesis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2025-03 date: 2024-03-19 date: 2024-03-19 name: Tongji University class: OTHER briefSummary: In recent years, obesity and its complications have severely threatened human health. Given the limited options for obesity treatment currently available, there is an urgent need to develop new drugs and therapeutic methods to alleviate patient suffering.